Australia's biotech startups fear new tax policies will hurt innovation
澳洲生物科技初創企業擔憂新稅務政策將損害創新
更新於: 2026年6月9日 上午02:45
Australia's vibrant biotechnology sector is currently facing significant uncertainty following proposed changes to the Research and Development Tax Incentive (RDTI) in the 2026-27 Federal Budget.
澳洲充滿活力的生物技術產業目前正處於巨大的不確定性中，原因是二〇二六至二〇二七年度聯邦預算案中針對研究與開發稅收優惠（RDTI）所提出的變更。
The government intends to limit the refundable tax offset to companies younger than 10 years, a move that has sparked alarm across the industry.
政府打算將可退還稅收抵免限制在成立不到十年的公司，此舉在整個產業引發了恐慌。
Health and life sciences organizations argue this policy is unworkable, as the path from research to market for life-saving medical products often spans 17 years or longer.
健康與生命科學組織認為這項政策不可行，因為救命醫療產品從研究到上市的過程往往長達十七年或更久。
Leaders fear that without this support, many home-grown companies may move their clinical programs and talent to more supportive overseas jurisdictions.
領導者們擔憂，若沒有這項支持，許多本土公司可能會將其臨床計畫和人才轉移到對其更友善的海外司法管轄區。
With the sector supporting 350,000 jobs and representing a massive export industry, concerns are growing that these new tax policies, combined with potential changes to Capital Gains Tax, could stifle innovation and discourage future investment in Australian health technology.
鑑於該產業支撐了三十五萬個工作職位，且代表著龐大的出口產業，人們日益擔憂這些新的稅收政策，加上資本利得稅可能發生的變更，可能會扼殺創新並阻礙對澳洲健康科技的未來投資。
